Alphyn Biologics Closes $3.3 Million Series A Financing To Advance Breakthrough Atopic Dermatitis Treatment
Alphyn Biologics Closes $3.3 Million Series A Financing To Advance Breakthrough Atopic Dermatitis Treatment
09/15/22, 11:35 AM
Location
annapolis
Money raised
$3.3 million
Industry
biotechnology
Round Type
series a
Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today that it is has closed a Series A financing round of approximately $3.3 million. The over-subscribed round was led by Queen City Angels, with participation from the Angel Physicians Fund and Serial Stage Venture Partners.
Company Info
Location
3724a thomas point road
annapolis, maryland, united states
Additional Info
Alphyn Biologics is a clinical-stage dermatology company developing first-in-class multi-target therapeutics for severe and prevalent skin diseases based on its AB-101 platform. Its lead product candidate, AB-101a, is a topical treatment for atopic dermatitis (AD), the most common form of eczema, currently in a Phase 2a clinical trial. AB-101a has demonstrated a strong safety profile and is in development to uniquely target AD's bacterial and immune system components, making it ideal for treating infected and non-infected AD. Alphyn's AB-101 platform has multiple bioactive compounds and, therefore, multiple mechanisms of action to support a robust pipeline of dermatologic therapeutics with potential safety, efficacy, and regulatory marketing authorization advantages. Alphyn is based in Annapolis, Maryland, and Cincinnati, Ohio, and has a wholly owned subsidiary in Australia. We became operational in 2020 and have raised approximately $6.7 million.